| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Protagonist Therapeutics, Inc. (PTGX) has 8 insiders with recent SEC Form 4 filings, including 5 buys and 5 sells. PTGX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 523.5K | $60.22M | - | |
| Other | 106.8K | $12.28M | - | |
| CFO | 60.8K | $6.99M | - | |
| Dir | 7.8K | $900.1K | - | |
| Dir | 7.8K | $900.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2017 | Shames Richard S. | Chief Medical Officer | Sale+OE | 2,017 | $19.00 | $38,323.00 | -100% | |
| Sep 12, 2017 | Shames Richard S. | Chief Medical Officer | Sell | 3,687 | $14.31 | $52,752.86 | -100% | |
| Aug 29, 2017 | Shames Richard S. | Chief Medical Officer | Sale+OE | 1,512 | $17.00 | $25,704.00 | -44.8% | |
| Aug 28, 2017 | Liu David Y | Chief Scientific Officer | Sale+OE | 3,500 | $15.00 | $52,500.00 | -63.6% | |
| Jul 10, 2017 | Liu David Y | Chief Scientific Officer | Sale+OE | 3,500 | $12.68 | $44,380.00 | -63.6% | |
| May 16, 2017 | Giraudo Bryan73 | Director | Buy | 10,000 | $6.46 | $64,566.00 | New | |
| Aug 16, 2016 | Johnson & Johnson59 | 10% Owner | Buy | 583,333 | $12.00 | $6,999,996.00 | +31.3% | |
| Aug 16, 2016 | Shanafelt Armen | Director, 10% Owner | Buy | 583,333 | $12.00 | $6,999,996.00 | +38.5% | |
| Aug 16, 2016 | Papanek Julie78 | Director | Buy | 583,333 | $12.00 | $6,999,996.00 | +31.2% | |
| Aug 16, 2016 | Canaan X L.P. | Director, 10% Owner | Buy | 583,333 | $12.00 | $6,999,996.00 | +31.2% |